<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>International Journal of Preventive Medicine (Int J Prev Med)</JournalTitle><Issn>2008-7802</Issn><Volume>11</Volume><Issue>7</Issue><PubDate PubStatus="epublish"><Year>2020</Year><Month>09</Month><Day>09</Day></PubDate></Journal><title locale="en_US">MS Care in Novel Coronavirus 19 Pandemic</title><FirstPage>2008</FirstPage><LastPage>7802</LastPage><Language>EN</Language><AuthorList><Author><affiliation locale="en_US">Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan</affiliation></Author><Author><affiliation locale="en_US">Isfahan Neurosciences Research Center &amp; Department of Neurology, School of Medicine,&#13;
Isfahan University of Medical Sciences, Isfahan</affiliation></Author><Author><affiliation locale="en_US">Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan &amp; Universal Council of Epidemiology, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran</affiliation></Author><Author><affiliation locale="en_US">Isfahan Neurosciences Research Center &amp; Department of Neurology, School of Medicine,&#13;
Isfahan University of Medical Sciences, Isfahan</affiliation></Author></AuthorList><History><PubDate PubStatus="received"><Year>2020</Year><Month>09</Month><Day>09</Day></PubDate></History><abstract locale="en_US">One hundred years after the influenza outbreak in 1918 coronavirus disease (COVID‑19) became a global health issue, which forces us to adapt our professional customs in the health care system. Our recent practice, since the&lt;br /&gt;1990s, of processing experimental and observational evidences and time‑consuming methods of developing guidelines seem not to be efficient enough because of scarce evidence and rapidly spreading disease. According&lt;br /&gt;to formal announcements, until writing this letter, we had more than 95,000 COVID‑19 patients in Iran with a mortality rate of 6.3%.</abstract><web_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/2306</web_url><pdf_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/download/2306/717718148</pdf_url></Article></Articles>
